NAFLD in 2014: Genetics, Diagnostics and Therapeutic Advances in NAFLD

Nat Rev Gastroenterol Hepatol. 2015 Feb;12(2):65-6. doi: 10.1038/nrgastro.2014.232. Epub 2015 Jan 6.

Abstract

In 2014, NAFLD was confirmed as the fastest growing aetiology for hepatocellular cancer in the USA. However, 2014 also saw progress in our understanding of the heritability and pathogenesis of NAFLD, and an important clinical trial targeting the farnesoid X receptor pathway has illustrated advances in developing a pharmacological therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Anticholesteremic Agents / therapeutic use
  • Carcinoma, Hepatocellular / etiology
  • Chenodeoxycholic Acid / analogs & derivatives
  • Chenodeoxycholic Acid / therapeutic use
  • Genetic Predisposition to Disease
  • Humans
  • Liver Neoplasms / etiology
  • Membrane Proteins / genetics
  • Non-alcoholic Fatty Liver Disease / complications
  • Non-alcoholic Fatty Liver Disease / diagnosis
  • Non-alcoholic Fatty Liver Disease / drug therapy
  • Non-alcoholic Fatty Liver Disease / genetics*

Substances

  • Anticholesteremic Agents
  • Membrane Proteins
  • TM6SF2 protein, human
  • obeticholic acid
  • Chenodeoxycholic Acid